A Retrospective Analysis of Thromboembolic Phenomena in Mechanically Ventilated Patients with COVID-19.
Journal
Critical care research and practice
ISSN: 2090-1305
Titre abrégé: Crit Care Res Pract
Pays: Egypt
ID NLM: 101539357
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
07
2020
revised:
27
11
2020
accepted:
30
12
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Recent studies have shown an increased prevalence of thromboembolic disease in critically ill patients with the novel SARS-CoV-2 disease (COVID-19). However, the use of enhanced anticoagulation therapy in these patients remains controversial. To determine the incidence of thromboembolic phenomena (TEP) and hemorrhagic events (HEs) in intensive care unit (ICU) COVID-19 patients. One hundred and sixty ICU patients with COVID-19 were enrolled. Clinical examination results, laboratory data, and imaging studies (computed tomography/Doppler ultrasound scans) for these patients were retrospectively collected and analyzed. Outcome measures including days on mechanical ventilation, ICU length of stay, and day-28 mortality were recorded. Sixty patients (37.5%) developed TEP including thirty patients with deep vein thrombosis, 55 patients with pulmonary embolism, and 7 patients with arterial thromboembolism. Cardiac arrhythmias, lymphocytopenia, and increased D-dimers were more frequently observed in the TEP group compared to the non-TEP group of patients (all The rates of TEP and HEs in mechanically ventilated critically ill COVID-19 patients were 37. 5% and 8.1%. Twenty-eight-day mortality was higher in the TEP group (60%) compared to the non-TEP group (30%) of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have shown an increased prevalence of thromboembolic disease in critically ill patients with the novel SARS-CoV-2 disease (COVID-19). However, the use of enhanced anticoagulation therapy in these patients remains controversial.
OBJECTIVES
OBJECTIVE
To determine the incidence of thromboembolic phenomena (TEP) and hemorrhagic events (HEs) in intensive care unit (ICU) COVID-19 patients.
METHODS
METHODS
One hundred and sixty ICU patients with COVID-19 were enrolled. Clinical examination results, laboratory data, and imaging studies (computed tomography/Doppler ultrasound scans) for these patients were retrospectively collected and analyzed. Outcome measures including days on mechanical ventilation, ICU length of stay, and day-28 mortality were recorded.
RESULTS
RESULTS
Sixty patients (37.5%) developed TEP including thirty patients with deep vein thrombosis, 55 patients with pulmonary embolism, and 7 patients with arterial thromboembolism. Cardiac arrhythmias, lymphocytopenia, and increased D-dimers were more frequently observed in the TEP group compared to the non-TEP group of patients (all
CONCLUSIONS
CONCLUSIONS
The rates of TEP and HEs in mechanically ventilated critically ill COVID-19 patients were 37. 5% and 8.1%. Twenty-eight-day mortality was higher in the TEP group (60%) compared to the non-TEP group (30%) of patients.
Identifiants
pubmed: 33520314
doi: 10.1155/2021/8737580
pmc: PMC7805521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8737580Informations de copyright
Copyright © 2021 Fahad Faqihi et al.
Déclaration de conflit d'intérêts
FF, AA, AB, NN, KA, FA, ZAM, SAA, and DK declare that there are no conflicts of interest. MB consults for EthosMedical, 410Medical, EchoNous, and Sonosim; none of these companies were aware of the study or had influence on it.
Références
Crit Care. 2020 Jun 2;24(1):275
pubmed: 32487122
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Respir Med Case Rep. 2020;31:101186
pubmed: 32834989
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
ACS Chem Neurosci. 2020 Aug 5;11(15):2156-2158
pubmed: 32709193
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
J Ultrasound Med. 2020 Aug 14;:
pubmed: 32797661
Crit Care. 2020 Jun 18;24(1):360
pubmed: 32552865
SAGE Open Med Case Rep. 2020 Oct 8;8:2050313X20964089
pubmed: 33101686
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):185-191
pubmed: 32133825
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112